Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG

glofitamab

Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6

Trial Locations (2)

NOT_YET_RECRUITING

Princess Margaret Cancer Centre, Toronto

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER